The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market

Davis Polk advised the representatives of the several underwriters in connection with Oculis Holding AG’s follow-on SEC-registered offering of an aggregate of 4,691,358 ordinary shares. Oculis conducted a concurrent registered direct offering in which it sold an aggregate of 740,740 ordinary shares. The combined offerings resulted in gross proceeds to Oculis of $110 million. Oculis’s ordinary shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market under the symbol “OCS.”

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease.

The Davis Polk corporate team included partner Derek Dostal and associates Nicole Groysman and Jean (Jean Young) Koo. The tax team included partner Ethan R. Goldman and associate Valentin Van de Walle. All members of the Davis Polk team are based in the New York office.

Copy link to share post